Q-omics provides the consensus-scored ZIK1 profile across patient tissues and cancer cell-line models. ZIK1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZIK1 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, ZIK1 RNA expression shows 19,425 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, COAD, and THYM as cancer lineages where ZIK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZIK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZIK1 survival associations across molecular data types. ZIK1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZIK1 RNA expression–survival associations across cancer types. High ZIK1 expression shows unfavorable associations in LGG, but favorable associations in HNSC, SCLC, KIRC, UVM and KIRP. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZIK1 RNA expression.
This table summarizes ZIK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ZIK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZIK1 shows lower tumor expression in COAD, THCA, UCEC, BRCA and KICH and higher tumor expression in CHOL. The COAD box plot shows higher ZIK1 RNA expression in normal versus tumor tissue (log2 FC = −0.552, t-test p < 0.001).
This table shows molecular features associated with ZIK1 in patient tissues and cancer cell lines. In patient samples, ZIK1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZIK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
